Anti-PDL1 Immunotherapy Demonstrates Efficacy in Phase 2 NSCLC Study
Genentech announced that in the large pivotal Phase 2 study, BIRCH, atezolizumab (MPDL3280A; anti-PDL1) met its primary endpoint and shrank tumors (objective response rate; ORR) in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease expressed PD-L1 (Programmed Death Ligand-1).
BIRCH is an open-label, multicenter, single-arm Phase 2 study that evaluated the safety and efficacy of atezolizumab in 667 people with locally advanced or metastatic NSCLC whose disease expressed PD-L1. The primary endpoint of the study was ORR. The study showed the amount of PD-L1 expressed by a person's cancer correlated with their response to the drug.
For more information call (800) 821–8590 or visit Gene.com.